Daxor announces further acquisitions, increased utilization of BVA-100

Daxor announces expansion of blood volume analysis into five of six hospitals in the Southeast and increased utilization for clinical use at two sites to guide fluid management in patients during the second quarter of 2023. The recent launch of Daxor’s ezBVA Lab service at quarter-end is anticipated to contribute significantly to growth of BVA sales, while providing additional validation for the use of BVA in the coming quarters based upon the pipeline of leads that have already expressed interest in the new offering. “Expanding commercialization with the addition of new hospital systems, new treatment areas, and growing clinical and health economic evidence of the benefit our diagnostic provides remains one our key priorities,” said Michael Feldschuh, Daxor’s CEO and President. “The recent launch of our ezBVA Lab service, which reduces test-related overhead and labor, is expected to accelerate adoption and enhance greater prescriber access to our BVA technology in the second half of this year.”